Nika Pharmaceuticals, Inc. (NIKA)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	0.06	0.1	0.06	0.18	0.01	0.01
Research & Development	-	-	-	3	-	-
Operating Expenses	0.06	0.1	0.06	3.18	0.01	0.01
Operating Income	-0.06	-0.1	-0.06	-3.18	-0.01	-0.01
Pretax Income	-0.06	-0.1	-0.06	-3.18	-0.01	-0.01
Net Income	-0.06	-0.1	-0.06	-3.18	-0.01	-0.01
Net Income to Common	-0.06	-0.1	-0.06	-3.18	-0.01	-0.01
Shares Outstanding (Basic)	1,059	1,022	876	724	396	396
Shares Outstanding (Diluted)	1,059	1,022	876	724	396	396
Shares Change (YoY)	20.91%	16.62%	21.02%	82.78%	-	-
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
EBIT	-0.06	-0.1	-0.06	-3.18	-0.01	-0.01

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.